Salute e Benessere

U.S. Institute of Peace Opens Nominations for 2023 Women Building Peace Award

The nominations period will run until July 31, 2023. USIP invites organizations and people across the globe to take part in identifying and honoring exceptional women who have dedicated their lives to building peace. The awardee will be recognized at a ceremony organized by USIP later in the year and will receive a cash prize. The nominations period will run untilJuly 31, 2023. USIP invites organizations and people across the globe to take part in identifying and honoring exceptional women...

Evaxion's AI technology identifies cancer vaccine targets associated with longer…

The clinical trial of the personalized cancer vaccine EVX-01 met its primary endpoints of safety and tolerabilityPositive clinical responses were reported in 8 out of 12 EVX-01 treated patientsHigh-quality neoantigens, predicted by AI technology, were associated with longer progression-free survivalStrong vaccine-specific immune responses were induced in all 12 EVX-01 treated patients Higher EVX-01 dose induced a stronger immune response and was associated with improved clinical...

Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data…

Jazz to host KOL investor webcast June 2, 2023, at 6:45 p.m. CT to review zanidatamab BTC data Jazz to host KOL investor webcastJune 2, 2023, at6:45 p.m. CTto review zanidatamab BTC data DUBLINandVANCOUVER, BC,June 3, 2023/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Zymeworks Inc. (Nasdaq: ZYME) today presented positive pivotal trial data, including new data on progression-free survival (PFS), from the Phase2bHERIZON-BTC-01 trial of the bispecific...

Autoinjectors Market worth $1.7 billion | MarketsandMarkets

Autoinjectors Market in terms of revenue was estimated to be worth $0.9 billion in 2023 and is poised to reach $1.7 billion by 2028, growing at a CAGR of 14.0% from 2023 to 2028 according to a new report by MarketsandMarkets™. Whereas, the autoinjector finished formulations market is projected to reach USD 136.5 billion in 2028 from USD 59.6 billion in 2023, growing a CAGR of 18.0%. Some of the prominent factors driving the growth of this market are favorable government support and…

Indivior Reaches Agreement with States' Attorneys General and District of…

"Indivior is focused on helping those who suffer from substance use disorders," said Mark Crossley, Chief Executive Officer. "We take our role as a responsible steward of medications for addiction and rescue extremely seriously. Resolving these legacy matters at the right value allows us to further this mission for patients," he added. "Indivior is focused on helping those who suffer from substance use disorders," saidMark Crossley, Chief Executive Officer. "We…

Clario Announces Strategic Partnership Supporting CancerX and White House Cancer…

The new partnership will leverage Clario's extensive experience in cancer trials. Over 50 years it has supported nearly 5,000 studies in over 160,000 sites worldwide involving more than 1 million patients. The new partnership will leverage Clario's extensive experience in cancer trials. Over 50 years it has supported nearly 5,000 studies in over 160,000 sites worldwide involving more than 1 million patients. Todd Rudo, Chief Medical Officer, Clario, outlined his goals for establishing...

Global Functional Genomics Market to Reach $46.24 Billion by 2033 - Exclusive…

According to this study, the global functional genomics market was valued at $10.57 billion in 2022 and is projected to reach $46.24 billion by 2033, growing at a CAGR of 14.04%. According to this study, the global functional genomics market was valued at$10.57 billionin 2022 and is projected to reach$46.24 billionby 2033, growing at a CAGR of 14.04%. The following factors are responsible for the increase in demand for functional genomics: The detailed study is a compilation of...

Liminal BioSciences Provides R&D Update

Eosinophil-driven diseases (EDD) such as eosinophilic asthma and atopic dermatitis represent a significant area of unmet need in global health. According to the World Health Organisation, globally, asthma, including eosinophilic and severe asthma, affected an estimated 262 million people in 2019 and caused 455,000 deaths. Eosinophil-driven diseases (EDD) such as eosinophilic asthma and atopic dermatitis represent a significant area of unmet need in global health. According to the World Health...

Novartis Kisqali® significantly reduced the risk of recurrence by 25% across a…

Kisqali is the first and only CDK4/6 inhibitor to demonstrate a consistent, clinically meaningful benefit across a broad population of patients with HR+/HER2- early breast cancer, regardless of disease stage, menopausal or nodal status 1 Results were also consistent across all secondary endpoints, including distant disease-free survival and recurrence-free survival, with a trend for improved overall survival *1 The safety profile of Kisqali was favorable at 400 mg with...

Three Key Insights On The Medical Equipment Industry 2023-2032, By The Global…

Three key insights on the industry: Three key insights on the industry: 1. Medical equipment industry revenue and its key drivers The global medical equipment market was valued at $647.4 billionin 2022. The market accounted for0.6% of the global GDP. The market is expected to grow at a compound annual growth rate(CAGR) of 8.1%during 2022 to 2032. 2. Medical equipment industry drivers Technological advancements such as 3. Largest medical equipment...

Scivita Medical's Headquarters, R&D and Manufacturing Plant Officially Opened

Dr Chin To, Scivita Medical's co-founder, General Manager, Chief Technology Officer, said: "The newly established headquarters, R&D and manufacturing plant is a significant milestone in Scivita Medical's journey, and it will play a big part in enhancing the comprehensive strength of Scivita Medical in all aspects. It will provide a significant boost to our production capacity, allowing us to meet the growing market demand while delivering more innovative and high-quality products…

Dragonfly Therapeutics to Present Phase 1 DF1001 Monotherapy Dose Escalation…

"We look forward to presenting our DF1001 Phase 1 study results at ASCO," said Joseph Eid, MD, President of Research and Development at Dragonfly Therapeutics. DF1001 is a first-in-class immune modulating TriNKET targeting HER2 that drives immune activation in solid tumors. DF1001 is also being evaluated in combination with nivolumab or nab paclitaxel. Clinical trial sites are open in the U.S., France, Belgium, Denmark and The Netherlands. Additional information about the trial…

BioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate…

BNT316/ONC-392 is a next-generation anti-CTLA-4 monoclonal antibody candidate jointly developed by BioNTech and OncoC4 as monotherapy or combination therapy in a range of solid tumor indications, includingnon-small cell lung cancer (NSCLC) Interim data of BNT316/ONC-392 from the ongoing Phase 1/2 trial to be presented at this year's ASCO Annual Meeting demonstrate encouraging signs of clinical anti-tumor activity and a manageable safety profile in patients with metastatic,...

Charcoal Facewash Market Anticipated to Garner $5,430.6 Million, Growing at a…

As per the report published by Research Dive, the global charcoal facewash market is expected to register a revenue of $5,430.6 million by 2031, at a CAGR of 5.3% during the forecast period 2022-2031. As per the report published by Research Dive, theglobal charcoal facewash market is expected to register a revenue of$5,430.6 millionby 2031, at a CAGR of 5.3% during the forecast period 2022-2031. Segments of the Charcoal Facewash Market The report has divided the charcoal...

Invivoscribe Partners with Complete Genomics to Develop and Commercialize…

"We are thrilled to be partnered with Complete Genomics worldwide, as they offer NGS platforms with excellent performance metrics, and lower cost systems and reagents vs. those provided by the other NGS providers," said Jeffrey Miller, CEO and CSO at Invivoscribe. "Our LeukoStrat® CDx FLT3 Mutation Assay is an internationally standardized, FDA and IVDR approved PCR-based capillary test that has proven invaluable as a companion diagnostic for three approved FLT3 targeted therapies…

Sobi to present new data at the 2023 EHA congress

Key data to be presented at the EHA congress 2023 Key data to be presented at the EHA congress 2023 Hemofili Samarbete Sobi/Apellis ...

OBI Pharma Announces Executive Leadership Management Change – Heidi Wang, Ph.D…

Dr. Wang appointed by the OBI Pharma Board of Directors as Chief Executive Officer to lead OBI Pharma with a vision and to bring innovative cancer therapies to patients globally. She brings a wealth of global executive management, regulatory, and drug approval experience in five therapeutic areas including cancer drug development, during a ~ 30-year tenure at Bristol Myers Squibb Company.TAIPEI, Taiwan, June02, 2023(GLOBE NEWSWIRE) -- OBI Pharma, Inc. (TPEx: 4174) | Effective...

Trajan's Microsampling Devices Meet IVDR Compliance in Europe, UK

Trajan has successfully fulfilled the required product safety and performance requirements under the In Vitro Diagnostic Medical Devices Regulation (IVDR) in Europe and the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom. Having earned this CE Mark regulatory compliance, Trajan expands the capabilities of its Neoteryx® microsampling products to provide decentralised, person-centered, minimally invasive blood collection in both clinical and research settings. ...

Orthonika awarded £1.34 million Innovate UK grant to accelerate development of…

Meniscus injury is severely debilitating, causing pain and restricted movement that limits everyday activities. Current treatment options are limited to suture repair or meniscal allografts, which are in short supply and lead to long waiting times. Where suture repair is not possible, the injured part or remaining meniscus is removed (meniscectomy) to alleviate symptoms in the short term. However, such patients are 14 times more likely to develop osteoarthritis. Meniscectomy has become...

Nicox: 2023 Ordinary Shareholder Meeting

Press Release Nicox: 2023 Ordinary Shareholder MeetingJune 2, 2023 – release at 7:30 am CETSophia Antipolis, France Nicox SA(Euronext Paris: FR0013018124, ALCOX), an international ophthalmology company, informs its shareholders that the Ordinary general meeting convened on first call on Thursday June 1 st, 2023, was not held as the quorum required by law was not reached.The shareholders of Nicox are thus convened on second call for an Ordinary general meeting on the same...

Kinarus Therapeutics Publishes Invitation to the 2023 Annual General Meeting

Basel, Switzerland , 2June 2023 .Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus” or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, today published the invitation to the 2023 Annual General Meeting ("AGM"), which will be held at 10 a.m. CEST on Wednesday, June 28, 2023 at the Radisson Blu Hotel Basel, Steinentorstrasse 25, 4051 Basel, Switzerland.For information on the…

Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive Officer Designate…

DUBLIN, June 1, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that Caroline J. Loew, Ph.D., has been appointed as the chief executive officer designate of Mural Oncology plc (Mural Oncology), the new independent public company to be established upon the planned separation of Alkermes' oncology business. Dr. Loew will join Alkermes in June as a strategic advisor and transition to CEO of Mural Oncology upon completion of the separation. DUBLIN,June 1, 2023/PRNewswire/...

CAMH study confirms ongoing brain inflammation associated with long COVID

Using advanced brain scanning with positron emission tomography (PET) imaging agents developed exclusively by the CAMH Brain Health Imaging Centre, study senior author Dr. Jeffrey Meyer and his study team found elevated levels of the protein TSPO, a brain marker of inflammation, in patients with onset of depression within several months after a COVID-19 infection. Using advanced brain scanning with positron emission tomography (PET) imaging agents developed exclusively by theCAMH Brain Health...

Transactions with shares and linked securities in Genmab A/S made by managerial…

Company Announcement COPENHAGEN, Denmark; June 1, 2023 –Genmab A/S (Nasdaq: GMAB) In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) made by managerial employees and their closely associated persons. The company's managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to...

Altri Comunicati